-
Mashup Score: 0
Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients infected with SARS-CoV-2 in the community and at high risk of severe outcomes from covid-19. Design Observational cohort study with the OpenSAFELY platform. Setting With the approval of NHS England, a real world…
Source: The BMJCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Treating Expecting Mothers With Sotrovimab for COVID-19 - 2 year(s) ago
Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI @DrJessicaT sat down to talk with us to discuss late breaking data using #Sotrovimab in this patient population during the era of #Omicron variant #IDWeek2022 https://t.co/bp1nhyXf8y
-
-
Mashup Score: 0Treating Expecting Mothers with Sotrovimab for COVID-19 - 2 year(s) ago
Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Dr. Jessica Tuan sat down to talk with us at #IDWeek2022 to discuss late breaking data using #Sotrovimab during the era of when the #Omicron variant was the predominant strain. https://t.co/bp1nhzeQ06
-
-
Mashup Score: 3Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals - 2 year(s) ago
This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#ResearchLetter: rapid development of sotrovimab resistance-associated mutations at positions S:E340 and S:P337 in a large proportion of high-risk #Omicron-infected patients following #sotrovimab, which was associated with delay in viral clearance. https://t.co/JsjMTvSHHY
-
-
Mashup Score: 0Top 5 Infectious Disease Stories of the Week-April 1, 2022 - 2 year(s) ago
Here is a rundown of the most popular stories we covered this past week.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Catch up with all the #infectiousdiseases news from the past week. #Pfizer #Moderna #FDA #sotrovimab #NIH https://t.co/Q0ZqIZE2p3
-
-
Mashup Score: 0
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Shown to be ineffective against the BA.2 Omicron subvariant, #sotrovimab distribution will be paused in areas where #BA2 is the dominant #COVID19 strain. https://t.co/QHq4waaKay
-
-
Mashup Score: 6
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI: Amid reports that #Sotrovimab does not effectively neutralize the BA.2 Omicron subvariant, the monoclonal antibody will no longer be dispersed in areas where #BA2Variant is dominant. https://t.co/2hRmT3My4u
-
-
Mashup Score: 9
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Breaking: There will be a pause in #sotrovimab distribution in regions where #BA2 is the dominant COVID-19 variant. Evidence suggests the monoclonal antibody therapy will not effectively neutralize the BA.2 Omicron subvariant. https://t.co/t8Fpa2kRx2
-
-
Mashup Score: 2
The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant. In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mostly along the east coast, following data showing that the authorized dose of the monoclonal
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The monoclonal antibody #sotrovimab is no longer authorized by the #FDA to treat #COVID19 in certain U.S. regions with high frequency of the #omicron #BA2 subvariant https://t.co/nslRLxp3ji
-
-
Mashup Score: 2COVID-19 Therapeutics Locator - 2 year(s) ago
The COVID-19 Therapeutics Locator is an interactive map that assists health care providers with identifying licensed and authorized locations where patients can fill prescriptions or receive therapy. The locator displays public locations with available courses of U.S. Government-procured COVID-19 therapeutics. These therapeutics are available under U.S. Food and Drug Administration (FDA)…
Categories: Healthcare Professionals, Latest HeadlinesTweet-
You can go to this link to find out where you can get #Paxlovid and other products authorized by the FDA for either prevention (#EvuSheld or treatment (Paxlovid, #sotrovimab, #bebtelovimab, and #molnupiravir) of #COVID19 https://t.co/Cyafew6G8J
-
🔍 New analysis suggests #sotrovimab remains beneficial in fully vaccinated #covid19 patients.💉🗣️📋 @Roxytonin @_ArlenWilcox @GSK @Vir_Biotech @bmj_latest 📖▶️ https://t.co/hcJLt5FM9W https://t.co/9MmUplZWnm